NCT05960617 is a Phase 2 clinical trial of Empagliflozin in Glycogen Storage Disease Type IB, sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.

Who is sponsoring NCT05960617?

NCT05960617 is sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT05960617?

Interventions in NCT05960617: Empagliflozin.

What condition does NCT05960617 study?

NCT05960617 studies Glycogen Storage Disease Type IB.

Is NCT05960617 still recruiting?

NCT05960617 is currently status unknown. Last updated 27 July 2023.

Last reviewed 2023-07-27 · How we verify

NCT05960617

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Empagliflozin in GSD-Ib Patients

Status unknown Phase 2 Last updated 27 July 2023

What this trial tests

Phase 2 trial testing Empagliflozin in Glycogen Storage Disease Type IB in 10 participants. Status unknown.

Timeline

15 July 2023

Primary endpoint
30 June 2024

31 December 2024

Quick facts

Lead sponsor	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	15 July 2023
Primary completion	30 June 2024
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Empagliflozin (empagliflozin) — full drug profile →

Conditions studied

Glycogen Storage Disease Type IB — all drugs for Glycogen Storage Disease Type IB →

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Who can join

Adults 1 to 50, any sex, with Glycogen Storage Disease Type IB. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Empagliflozin Treatment of GSD-1b patients

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care.
Rossi A, Simeoli C, Pivonello R, Salerno M, et al · · 2024 · cited 3× · PMID 38556561 · DOI 10.1007/s11154-024-09880-2

Verify or expand the search:

Other trials of Empagliflozin

Trials testing the same drug.

NCT07060417 — Vascular Effects of SGLT2i in Non-diabetic CKD · Phase 2 · not yet recruiting
NCT06625073 — Randomized Trial of SGLT2i in Heart Transplant Recipients · Phase 4 · recruiting
NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting
NCT07214818 — SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome · Phase 2, PHASE3 · active not recruiting
NCT07180745 — Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease · Phase 4 · not yet recruiting

Other Xinhua Hospital, Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07506811 — Effects of Different Music Tempos on Feeding Outcomes in Preterm Infants · NA · not yet recruiting
NCT07441187 — Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type · not yet recruiting
NCT07375602 — A Multimodal AI Prediction Model for Complications After Transcatheter Closure of Perimembranous VSD in Children · recruiting
NCT07405658 — Clinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for Ear · not yet recruiting
NCT07381400 — Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Stu · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05960617 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Last refreshed: 27 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05960617.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing